Abstract
Serine proteases (SP), such as thrombin, factor Xa, elastase, trypsin are implicated in many clinical disorders such as emphysema, arthritis and cardiovascular diseases. These enzymes, in normal physiological conditions, are regulated by naturally occurring serine protease inhibitors, such as anti-thrombin III involved in thromb in inhibition. Primitive parasitic invertebrates have co-evolved highly specific mechanisms to communicate with their hosts for survival purposes, by blocking host processes such as blood coagulation. Thus a battery of new powerful molecules from blood-sucker animals acting at different points of the coagulation cascade such like factor Xa, thrombin, platelets aggregation inhibitors have been isolated and are now at a clinical level. In this review, we focus our attention on thrombin inhitors.
Keywords: thrombin inhibitors, serine proteases (sp), thrombin, factor Xa, elastase, trypsin, hirudin, hirudins, hirulogs, Proteolytic enzymes
Current Pharmaceutical Design
Title: Leech Thrombin Inhibitors
Volume: 8 Issue: 7
Author(s): Michel Salzet
Affiliation:
Keywords: thrombin inhibitors, serine proteases (sp), thrombin, factor Xa, elastase, trypsin, hirudin, hirudins, hirulogs, Proteolytic enzymes
Abstract: Serine proteases (SP), such as thrombin, factor Xa, elastase, trypsin are implicated in many clinical disorders such as emphysema, arthritis and cardiovascular diseases. These enzymes, in normal physiological conditions, are regulated by naturally occurring serine protease inhibitors, such as anti-thrombin III involved in thromb in inhibition. Primitive parasitic invertebrates have co-evolved highly specific mechanisms to communicate with their hosts for survival purposes, by blocking host processes such as blood coagulation. Thus a battery of new powerful molecules from blood-sucker animals acting at different points of the coagulation cascade such like factor Xa, thrombin, platelets aggregation inhibitors have been isolated and are now at a clinical level. In this review, we focus our attention on thrombin inhitors.
Export Options
About this article
Cite this article as:
Salzet Michel, Leech Thrombin Inhibitors, Current Pharmaceutical Design 2002; 8 (7) . https://dx.doi.org/10.2174/1381612023395664
DOI https://dx.doi.org/10.2174/1381612023395664 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetic Resonance Contrast Media Sensing In Vivo Molecular Imaging Agents: An Overview
Current Radiopharmaceuticals Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Wnt Signaling in Angiogenesis
Current Drug Targets Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Clearance of Amyloid-β Peptide by Neuronal and Non-Neuronal Cells: Proteolytic Degradation by Secreted and Membrane associated Proteases
Current Neurovascular Research Tracking Stem Cell Therapy in the Myocardium: Applications of Positron Emission Tomography
Current Pharmaceutical Design Pitavastatin Improves Endothelial Function and Glucose Metabolism in Ovariectomized Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Modulation of Alzheimers Amyloidosis by Statins: Mechanisms of Action
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Application of Nanomaterials in Water Treatment: Arsenic and Natural Organic Matter Removal
Recent Patents on Nanotechnology Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Novel Antimicrobial Agents for the Management of Maxillofacial and Neck Infections
Recent Patents on Anti-Infective Drug Discovery The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Co-Morbidity and Self Medication in Schizophrenia: Involvement of Endogenous Morphine Signaling Mechanisms
Current Drug Targets Peroxynitrite-Mediated Structural Changes in Histone H2A: Biochemical and Biophysical Analysis
Protein & Peptide Letters Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies